Utilizing a novel mitochondrial-related gene signature for predicting the prognosis and immunological impact in bladder cancer

Gongping Wu; Chengwei Fan; Xueming Ma; Dongnuan Yao; Weitao Yu; Junqiang Tian

doi:10.1007/s12672-025-03927-9

November 18, 2025Discover OncologyOpen Access

Utilizing a novel mitochondrial-related gene signature for predicting the prognosis and immunological impact in bladder cancer

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate a mitochondrial-related gene signature for prognosis and immunological analysis in bladder cancer.
Developed a mitochondrial risk model.
Validated the model to ensure its effectiveness.
Used the model for prognosis stratification in bladder cancer.
The mitochondrial risk model serves as a clinically actionable biomarker.
It improves prognosis predictions for bladder cancer patients.
The model aids in selecting personalized therapeutic options.

Implication

Novel biomarker improves prognosis prediction in bladder cancer, suggesting better personalized treatment selection.

Abstract

This validated mitochondrial risk model delivers a clinically actionable biomarker for BLCA prognosis stratification and guides personalized therapeutic selection, enabling precision treatment intensification.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wu et al. (2025) studied this question.

synapsesocial.com/papers/6924fee6c0ce034ddc3516f6 https://doi.org/10.1007/s12672-025-03927-9

View Full Paper

Ask AI

Bookmark

Share

Utilizing a novel mitochondrial-related gene signature for predicting the prognosis and immunological impact in bladder cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Utilizing a novel mitochondrial-related gene signature for predicting the prognosis and immunological impact in bladder cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading